**1. Phylogeny:**  
Non‐receptor tyrosine‐protein kinase TYK2 belongs to the Janus kinase (JAK) family, a group of non‐receptor tyrosine kinases that mediate cytokine receptor signaling. TYK2 is evolutionarily related to other JAK family members such as JAK1, JAK2, and JAK3, and its orthologs have been identified across a broad spectrum of mammalian species, indicating its conservation among vertebrates (wang2025atripleactioninhibitory pages 1-5, korcz1995tyrosineproteinkinase pages 6-7). The phylogenetic analyses performed by Manning et al. (2002) established that the JAK family arose early in metazoan evolution through gene duplication events, and TYK2 represents one branch that has retained unique structural and functional features compared with receptor tyrosine kinases (RTKs) and other non‐receptor tyrosine kinases (wang2025atripleactioninhibitory pages 1-5, loris2007exploringstructureand pages 27-28). Within the human kinome, TYK2 falls into the tyrosine kinase (TK) group and specifically within the non‐receptor class, setting it apart from the approximately 20 receptor tyrosine kinases that signal through extracellular ligand engagement (korcz1995tyrosineproteinkinase pages 4-6, loris2007exploringstructureand pages 43-46). Its close evolutionary relationship with other cytokine‐associated kinases suggests that TYK2 and its paralogs share a common ancestral gene that was already present in early eukaryotic ancestors, thereby forming part of the conserved JAK–STAT signaling machinery (wang2025atripleactioninhibitory pages 1-5, loris2007exploringstructureand pages 16-21).

**2. Reaction Catalyzed:**  
TYK2 catalyzes the transfer of a phosphate group from ATP to specific tyrosine residues on substrate proteins. In the canonical reaction, one molecule of ATP and a protein substrate containing a tyrosine residue are converted into ADP and a phosphorylated tyrosine residue on the protein, with the concomitant release of a proton (H^+). This phosphorylation reaction is central to its role in mediating cytokine receptor signaling as it creates docking sites for downstream signaling molecules, notably members of the Signal Transducer and Activator of Transcription (STAT) family (wang2025atripleactioninhibitory pages 1-5, reys2022insilicoprofiling pages 29-32). The reaction thus can be summarized as:  
ATP + [protein]–Tyr → ADP + [protein]–Tyr‑phosphate + H^+ (wang2025atripleactioninhibitory pages 1-5, loris2007exploringstructureand pages 43-46).  
This catalytic activity is essential for the initiation of multiple signaling cascades following cytokine binding to receptor complexes, leading to subsequent gene transcription events (wang2025atripleactioninhibitory pages 14-17).

**3. Cofactor Requirements:**  
The catalytic activity of TYK2 is dependent on the binding of ATP and the presence of divalent metal ions, most commonly magnesium (Mg^2+), which serve as essential cofactors. Mg^2+ ions coordinate with the phosphate groups of ATP within the active site and stabilize the transition state during the phosphoryl transfer reaction (wang2025atripleactioninhibitory pages 5-8, reys2022insilicoprofiling pages 29-32). The requirement for Mg^2+ is shared among protein kinases and is critical for proper ligand positioning within the ATP‐binding pocket of TYK2’s catalytic domain (loris2007exploringstructureand pages 68-72). This cofactor dependency ensures that only properly formed enzyme–substrate complexes proceed toward efficient catalysis, thus contributing to the fidelity of downstream signaling events (wang2025atripleactioninhibitory pages 1-5).

**4. Substrate Specificity:**  
TYK2 preferentially targets tyrosine residues on substrate proteins that are associated with cytokine receptor complexes. The intrinsic substrate specificity of TYK2 aligns with the general characteristics of the human tyrosine kinome, where studies have reported that tyrosine kinases typically display distinct sequence preferences flanking target tyrosine sites (wang2025atripleactioninhibitory pages 5-8, wang2025atripleactioninhibitory pages 8-11). In the context of cytokine signaling, TYK2 phosphorylates multiple receptor chains such as IFNAR1, IL12RB1, IL10RB, and IL13RA1, thereby creating phosphotyrosine docking sites that facilitate the recruitment of STAT proteins (korcz1995tyrosineproteinkinase pages 4-6, wang2025atripleactioninhibitory pages 5-8). Although a defined consensus motif has not been fully established for TYK2, its substrate specificity is influenced by the local amino acid environment of the tyrosine residue—typically favoring a configuration that supports receptor recruitment and efficient STAT docking (wang2025atripleactioninhibitory pages 8-11, loris2007exploringstructureand pages 76-77). Recent high‐throughput studies in the tyrosine kinase family have begun to delineate preferences for flanking residues; such studies indicate that key determinants include hydrophobic and acidic residues adjacent to the phosphorylated tyrosine, although the precise motif for TYK2 remains to be comprehensively defined (wang2025atripleactioninhibitory pages 8-11).

**5. Structure:**  
TYK2 is characterized by a modular architecture composed of several distinct domains that collectively contribute to its functional roles. The N-terminal region contains a FERM (4.1 protein, ezrin, radixin, moesin) domain followed by an SH2 (Src Homology 2) domain, both of which are responsible for mediating interactions with cytokine receptor chains (korcz1995tyrosineproteinkinase pages 6-7, loris2007exploringstructureand pages 43-46). Adjacent to these receptor‐interaction domains lies the pseudokinase domain (JH2), which, despite its ability to bind ATP, lacks full catalytic activity; it serves primarily a regulatory role by modulating the conformational state of the adjacent kinase domain. The C-terminal catalytic domain (JH1) of TYK2 exhibits the conserved bilobal architecture characteristic of protein kinases, with an N-lobe composed of β-sheets and a C-helix, and a larger C-lobe that is predominantly α-helical (wang2025atripleactioninhibitory pages 1-5, wang2025atripleactioninhibitory pages 11-14). Key catalytic motifs within the JH1 domain include the VAVK motif, in which a lysine residue is critical for ATP binding, the HRD motif that contributes an aspartate acting as a catalytic base, and the DFG motif that coordinates divalent metal ions and is essential for facilitating phosphoryl transfer (wang2025atripleactioninhibitory pages 1-5, loris2007exploringstructureand pages 76-77, reys2022insilicoprofiling pages 29-32). Structural studies suggest that TYK2 undergoes significant conformational changes upon activation; for instance, models indicate a dramatic 230° rotation of the kinase domain relative to the pseudokinase domain in the transition from an autoinhibited to an active state (wang2025atripleactioninhibitory pages 11-14, wang2025atripleactioninhibitory pages 32-43). The presence of multiple phosphorylatable tyrosine residues distributed across the JH1 and JH2 domains further contributes to its regulatory complexity by providing docking sites for downstream signaling partners (wang2025atripleactioninhibitory pages 5-8, korcz1995tyrosineproteinkinase pages 6-7). These structural features, derived from both crystallographic and modeling studies, underscore the dual role of TYK2 as both a catalytic enzyme and a scaffold for assembling cytokine receptor complexes (wang2025atripleactioninhibitory pages 1-5, loris2007exploringstructureand pages 28-33).

**6. Regulation:**  
Regulation of TYK2 activity is achieved through a combination of autoinhibitory domain interactions, phosphorylation events, and allosteric modulation. In its basal state, TYK2 exists predominantly in an autoinhibited conformation wherein the pseudokinase (JH2) domain interacts with the catalytic kinase (JH1) domain to restrict access to the ATP‐binding site, thereby minimizing unintended catalytic activity (wang2025atripleactioninhibitory pages 5-8, loris2007exploringstructureand pages 52-54). Upon cytokine binding to the receptor complex, receptor dimerization facilitates trans‐phosphorylation events that disrupt this autoinhibitory interaction; key tyrosine residues—such as pY292, pY433, pY604, and pY827—become phosphorylated, enabling a conformational shift that releases the inhibition and allows full activation of the kinase activity (wang2025atripleactioninhibitory pages 17-21, wang2025atripleactioninhibitory pages 14-17). In addition to trans-phosphorylation, allosteric inhibitors have been developed that target the JH2 pseudokinase domain. For example, compounds like deucravacitinib (DEU) selectively bind within the pseudokinase domain, thereby stabilizing the autoinhibited conformation, competitively inhibiting ATP binding in JH2, and sterically preventing the correct assembly of an active receptor–kinase heterodimer (wang2025atripleactioninhibitory pages 5-8, wang2025atripleactioninhibitory pages 32-43). Thus, the regulation of TYK2 is mediated by reversible phosphorylation, conformational rearrangements, and allosteric ligand binding, all of which play essential roles in controlling its kinase activity in a cytokine‐dependent manner (wang2025atripleactioninhibitory pages 8-11, loris2007exploringstructureand pages 77-80).

**7. Function:**  
TYK2 serves as a critical signaling mediator in the innate and adaptive immune systems by transducing signals from a variety of cytokine receptors. Upon engagement of cytokines—such as interferons (IFN‑α/β) and interleukins—the receptor complex, which includes a TYK2-associated receptor chain (e.g., IFNAR1, IL12RB1, IL10RB, or IL13RA1) and a partner chain associated with JAK1 or JAK2, undergoes dimerization. This event promotes reciprocal trans‐phosphorylation events that enable TYK2 to phosphorylate specific tyrosine residues on both the receptor chains and downstream substrates, notably STAT transcription factors (wang2025atripleactioninhibitory pages 1-5, cheung2024immunologicalandsocial pages 38-43). Phosphorylated STATs then dimerize, translocate to the nucleus, and modulate the expression of genes involved in immune responses, cell growth, and differentiation (wang2025atripleactioninhibitory pages 1-5, korcz1995tyrosineproteinkinase pages 6-7). In addition to its canonical role in propagating cytokine signals, TYK2 also exerts regulatory functions by negatively modulating STAT3 activity through phosphorylation at specific sites that differ from those typically used to activate STAT signaling (wang2025atripleactioninhibitory pages 1-5, wang2025atripleactioninhibitory pages 17-21). Tissue expression patterns indicate that TYK2 is ubiquitously expressed but is particularly crucial in immune cells, where it orchestrates a rapid response to viral infections and other immune challenges by mediating interferon signaling (cheung2024immunologicalandsocial pages 38-43, korcz1995tyrosineproteinkinase pages 6-7). Moreover, the interactions between TYK2 and its associated receptor chains define its role as both a catalytic enzyme and a scaffold, ensuring precise temporal and spatial coordination of downstream signals (wang2025atripleactioninhibitory pages 14-17, loris2007exploringstructureand pages 21-24).

**8. Other Comments:**  
Clinically, TYK2 has emerged as an attractive therapeutic target for autoimmune and inflammatory diseases due to its pivotal role in cytokine signaling. Selective inhibitors—such as deucravacitinib—have been developed to target the allosteric regulatory pseudokinase domain of TYK2, effectively reducing its kinase activity by stabilizing its autoinhibited conformation and preventing receptor complex assembly (wang2025atripleactioninhibitory pages 24-32, wang2025atripleactioninhibitory pages 5-8). Such inhibitors demonstrate high specificity, with reported potency on the order of sub-nanomolar IC50 values, and are under investigation for their potential to modulate aberrant immune responses in disorders like psoriasis (wang2025atripleactioninhibitory pages 32-43, loris2007exploringstructureand pages 52-54). In addition to pharmacological inhibitors, mutations that affect TYK2 function or expression have been linked to immunodeficiencies and dysregulated cytokine signaling, although detailed mutational spectra are less well documented in the available context (korcz1995tyrosineproteinkinase pages 4-6, wang2025atripleactioninhibitory pages 8-11). Overall, TYK2’s dual role as both a catalytic and scaffolding protein in cytokine receptor complexes underlines its importance in maintaining immune homeostasis and highlights the therapeutic promise of its targeted modulation (wang2025atripleactioninhibitory pages 14-17, cheung2024immunologicalandsocial pages 38-43).

**9. References:**  
1. Wang, J., Lomakin, I. B., Batista, V. S., & Bunick, C. G. “A triple‐action inhibitory mechanism of allosteric tyk2‐specific inhibitors.” Journal of Investigative Dermatology, May 2025. URL: https://doi.org/10.1016/j.jid.2025.04.025 (pages 1-5, 5-8, 8-11, 11-14, 14-17, 17-21, 21-24, 24-32, 32-43).  
2. Cheung, C. C. “Immunological and social determinants of asthma: from cytokine signaling to air pollution disparities.” 2024 (pages 38-43).  
3. Korcz, A., Soprano, D. R., & Soprano, K. J. “Tyrosine protein kinase expression in long‐term quiescent WI‐38 cells following growth factor stimulation.” Journal of Cellular Biochemistry, Sep 1995. URL: https://doi.org/10.1002/jcb.240590106 (pages 4-6, 6-7).  
4. Loris, M. “Exploring structure and plasticity of tyrosine kinase domains for drug discovery.” 2007, Unknown journal (pages 11-16, 27-28, 28-33, 43-46, 52-54, 59-63, 68-72, 72-75, 75-76, 76-77, 77-80, 80-84, 138-143, 143-146, 146-149, 149-152, 152-155).  
5. Reys, V. “In silico profiling of protein-kinases inhibitors and study of protein-protein interactions.” 2022, Unknown journal (pages 29-32, 32-35, 35-38).  
6. Southekal, S. “Integrative analysis of multi-omics kinome data and virtual screening of identified targets with pan-cancer application.” 2021, Unknown journal (pages 11-19, 19-25, 120-124).  
7. Bajusz, D. et al. “Sh2db, an information system for the sh2 domain.” Nucleic Acids Research, May 2023. URL: https://doi.org/10.1093/nar/gkad420 (pages 4-5, 11-11).  
8. Guo, Y. “Learning covid-19 network from literature databases using core decomposition.” 2021, Unknown journal (pages 24-31).  
9. Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002). “The protein kinase complement of the human genome.” Science, 298(5600), 1912-1934.  
10. Manning, G., Plowman, G. D., Hunter, T., & Sudarsanam, S. (2002). “Evolution of protein kinase signaling from yeast to man.” Trends in Biochemical Sciences, 27(10), 514-520.

References

1. (wang2025atripleactioninhibitory pages 1-5): Jimin Wang, Ivan B. Lomakin, Victor S. Batista, and Christopher G. Bunick. A triple-action inhibitory mechanism of allosteric tyk2-specific inhibitors. Journal of Investigative Dermatology, May 2025. URL: https://doi.org/10.1016/j.jid.2025.04.025, doi:10.1016/j.jid.2025.04.025. This article has 2 citations and is from a highest quality peer-reviewed journal.
2. (wang2025atripleactioninhibitory pages 11-14): Jimin Wang, Ivan B. Lomakin, Victor S. Batista, and Christopher G. Bunick. A triple-action inhibitory mechanism of allosteric tyk2-specific inhibitors. Journal of Investigative Dermatology, May 2025. URL: https://doi.org/10.1016/j.jid.2025.04.025, doi:10.1016/j.jid.2025.04.025. This article has 2 citations and is from a highest quality peer-reviewed journal.
3. (wang2025atripleactioninhibitory pages 17-21): Jimin Wang, Ivan B. Lomakin, Victor S. Batista, and Christopher G. Bunick. A triple-action inhibitory mechanism of allosteric tyk2-specific inhibitors. Journal of Investigative Dermatology, May 2025. URL: https://doi.org/10.1016/j.jid.2025.04.025, doi:10.1016/j.jid.2025.04.025. This article has 2 citations and is from a highest quality peer-reviewed journal.
4. (wang2025atripleactioninhibitory pages 24-32): Jimin Wang, Ivan B. Lomakin, Victor S. Batista, and Christopher G. Bunick. A triple-action inhibitory mechanism of allosteric tyk2-specific inhibitors. Journal of Investigative Dermatology, May 2025. URL: https://doi.org/10.1016/j.jid.2025.04.025, doi:10.1016/j.jid.2025.04.025. This article has 2 citations and is from a highest quality peer-reviewed journal.
5. (wang2025atripleactioninhibitory pages 5-8): Jimin Wang, Ivan B. Lomakin, Victor S. Batista, and Christopher G. Bunick. A triple-action inhibitory mechanism of allosteric tyk2-specific inhibitors. Journal of Investigative Dermatology, May 2025. URL: https://doi.org/10.1016/j.jid.2025.04.025, doi:10.1016/j.jid.2025.04.025. This article has 2 citations and is from a highest quality peer-reviewed journal.
6. (wang2025atripleactioninhibitory pages 8-11): Jimin Wang, Ivan B. Lomakin, Victor S. Batista, and Christopher G. Bunick. A triple-action inhibitory mechanism of allosteric tyk2-specific inhibitors. Journal of Investigative Dermatology, May 2025. URL: https://doi.org/10.1016/j.jid.2025.04.025, doi:10.1016/j.jid.2025.04.025. This article has 2 citations and is from a highest quality peer-reviewed journal.
7. (cheung2024immunologicalandsocial pages 38-43): CCL Cheung. Immunological and social determinants of asthma: from cytokine signaling to air pollution disparities. Unknown journal, 2024.
8. (korcz1995tyrosineproteinkinase pages 4-6): Aleksandra Korcz, Dianne Robert Soprano, and Kenneth J. Soprano. Tyrosine protein kinase expression in long‐term quiescent wi‐38 cells following growth factor simulation. Journal of Cellular Biochemistry, 59:42-52, Sep 1995. URL: https://doi.org/10.1002/jcb.240590106, doi:10.1002/jcb.240590106. This article has 2 citations and is from a peer-reviewed journal.
9. (korcz1995tyrosineproteinkinase pages 6-7): Aleksandra Korcz, Dianne Robert Soprano, and Kenneth J. Soprano. Tyrosine protein kinase expression in long‐term quiescent wi‐38 cells following growth factor simulation. Journal of Cellular Biochemistry, 59:42-52, Sep 1995. URL: https://doi.org/10.1002/jcb.240590106, doi:10.1002/jcb.240590106. This article has 2 citations and is from a peer-reviewed journal.
10. (loris2007exploringstructureand pages 28-33): M Loris. Exploring structure and plasticity of tyrosine kinase domains for drug discovery. Unknown journal, 2007.
11. (loris2007exploringstructureand pages 52-54): M Loris. Exploring structure and plasticity of tyrosine kinase domains for drug discovery. Unknown journal, 2007.
12. (wang2025atripleactioninhibitory pages 14-17): Jimin Wang, Ivan B. Lomakin, Victor S. Batista, and Christopher G. Bunick. A triple-action inhibitory mechanism of allosteric tyk2-specific inhibitors. Journal of Investigative Dermatology, May 2025. URL: https://doi.org/10.1016/j.jid.2025.04.025, doi:10.1016/j.jid.2025.04.025. This article has 2 citations and is from a highest quality peer-reviewed journal.
13. (wang2025atripleactioninhibitory pages 32-43): Jimin Wang, Ivan B. Lomakin, Victor S. Batista, and Christopher G. Bunick. A triple-action inhibitory mechanism of allosteric tyk2-specific inhibitors. Journal of Investigative Dermatology, May 2025. URL: https://doi.org/10.1016/j.jid.2025.04.025, doi:10.1016/j.jid.2025.04.025. This article has 2 citations and is from a highest quality peer-reviewed journal.
14. (loris2007exploringstructureand pages 16-21): M Loris. Exploring structure and plasticity of tyrosine kinase domains for drug discovery. Unknown journal, 2007.
15. (loris2007exploringstructureand pages 21-24): M Loris. Exploring structure and plasticity of tyrosine kinase domains for drug discovery. Unknown journal, 2007.
16. (loris2007exploringstructureand pages 68-72): M Loris. Exploring structure and plasticity of tyrosine kinase domains for drug discovery. Unknown journal, 2007.
17. (reys2022insilicoprofiling pages 29-32): V Reys. In silico profiling of protein-kinases inhibitors and study of protein-protein interactions. Unknown journal, 2022.
18. (loris2007exploringstructureand pages 27-28): M Loris. Exploring structure and plasticity of tyrosine kinase domains for drug discovery. Unknown journal, 2007.
19. (loris2007exploringstructureand pages 77-80): M Loris. Exploring structure and plasticity of tyrosine kinase domains for drug discovery. Unknown journal, 2007.
20. (loris2007exploringstructureand pages 43-46): M Loris. Exploring structure and plasticity of tyrosine kinase domains for drug discovery. Unknown journal, 2007.
21. (loris2007exploringstructureand pages 76-77): M Loris. Exploring structure and plasticity of tyrosine kinase domains for drug discovery. Unknown journal, 2007.